ARQT Arcutis Biotherapeutics Forecast, Technical & Fundamental Analysis
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs... Show more
ARQT is expected to report earnings to fall 147.22% to 4 cents per share on July 30
Q2'26
Est.
$0.04
Q1'26
Missed
by $0.04
Q4'25
Beat
by $0.05
Q3'25
Beat
by $0.15
Q2'25
Beat
by $0.04
The last earnings report on May 06 showed earnings per share of -9 cents, missing the estimate of -5 cents. With 1.33M shares outstanding, the current market capitalization sits at 3.05B.
A.I. Advisor
published General Information
General Information
a company, which engages in the development and commercialization of treatments for dermatological diseases.
A.I.dvisor indicates that over the last year, ARQT has been loosely correlated with XNCR. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ARQT jumps, then XNCR could also see price increases.
ARQT in upward trend: price rose above 50-day moving average on June 09, 2026
ARQT moved above its 50-day moving average on June 09, 2026 date and that indicates a change from a downward trend to an upward trend. In of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 01, 2026. You may want to consider a long position or call options on ARQT as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ARQT just turned positive on May 27, 2026. Looking at past instances where ARQT's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARQT advanced for three days, in of 290 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 50-day moving average for ARQT moved below the 200-day moving average on May 14, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARQT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ARQT broke above its upper Bollinger Band on June 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ARQT entered a downward trend on May 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ARQT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.077) is normal, around the industry mean (18.720). P/E Ratio (0.000) is within average values for comparable stocks, (36.072). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.682). ARQT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (7.513) is also within normal values, averaging (357.550).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARQT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
